ImpediMed Limited
IPD
Rank in Stocks
#28689
Operating as a medical software technology provider, ImpediMed Limited is... Operating as a medical software technology provider, ImpediMed Limited is responsible for the development, production, and global sales of bioimpedance spectroscopy (BIS) instruments and accompanying software solutions, serving markets in Australia, North America, and internationally. Its product portfolio features SOZO, a non-invasive BIS device used for evaluating lymphedema and tracking fluid levels in heart failure patients. Additionally, it offers the SFB7, a single-channel, tetrapolar BIS instrument for analyzing body composition in healthy individuals, and ImpediVET, another single-channel, tetrapolar BIS device specifically designed for veterinary applications to measure fluid status and tissue composition. ImpediMed primarily sells its technology to hospitals and clinics. This Australian-headquartered firm, based in Pinkenba, was established in 1999.
Share Price
$0.00276876
Last synced: 2026-11-09
Market Cap
$10.15M
Change (1 day)
33.09%
Change (1 year)
-88.55%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade ImpediMed Limited (IPD)
Category
Healthcare
Earnings for ImpediMed Limited (IPD)
Earnings in Jun 2026 TTM: $-17.74M
According to ImpediMed Limited's latest financial reports, its current earnings (TTM) are $-17.74M. In 2025 the company earned $-15.28M, a decrease compared to its 2024 earnings of $-13.84M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for ImpediMed Limited from 2008 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-17.74M | 16.12% |
| 2025 | $-15.28M | 10.42% |
| 2024 | $-13.84M | -5.92% |
| 2023 | $-14.71M | -0.57% |
| 2022 | $-14.79M | -12.14% |
| 2021 | $-16.84M | 1.95% |
| 2020 | $-16.52M | -1.79% |
| 2019 | $-16.82M | -16.54% |
| 2018 | $-20.15M | -4.96% |
| 2017 | $-21.20M | 9.54% |
| 2016 | $-19.35M | 69.88% |
| 2015 | $-11.39M | 52.21% |
| 2014 | $-7.48M | -3.23% |
| 2013 | $-7.73M | -38.68% |
| 2012 | $-12.61M | -20.63% |
| 2011 | $-15.89M | 64.58% |
| 2010 | $-9.66M | -14.92% |
| 2009 | $-11.35M | 21.30% |
| 2008 | $-9.36M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $6.56B | -37,082.51% |
US
|
|
| $6.60B | -37,313.58% |
IE
|
|
| $5.12B | -28,933.05% |
US
|
|
| $3.66B | -20,699.06% |
US
|
|
| $1.43B | -8,172.80% |
US
|
Questions about ImpediMed Limited's net income
What is ImpediMed Limited's net income?
ImpediMed Limited's net income over the last twelve months is $-17.74M, as of Jun 2026.
What was ImpediMed Limited's net income in 2025?
In 2025, ImpediMed Limited's net income was $-15.28M, compared with $-13.84M in 2024.
How has ImpediMed Limited's net income changed since 2020?
From 2020 to 2025, ImpediMed Limited's net income was highest in 2024 ($-13.84M) and lowest in 2021 ($-16.84M).
How does ImpediMed Limited's net income compare with similar companies?
ImpediMed Limited's net income ($-17.74M) is lower than that of all 5 similar companies listed above. The highest among them is Medtronic plc, with $6.60B.